290 related articles for article (PubMed ID: 12496961)
1. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
Leitner WW; Hwang LN; deVeer MJ; Zhou A; Silverman RH; Williams BR; Dubensky TW; Ying H; Restifo NP
Nat Med; 2003 Jan; 9(1):33-9. PubMed ID: 12496961
[TBL] [Abstract][Full Text] [Related]
2. Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.
Leitner WW; Bergmann-Leitner ES; Hwang LN; Restifo NP
Vaccine; 2006 Jun; 24(24):5110-8. PubMed ID: 16725231
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
Goldberg SM; Bartido SM; Gardner JP; Guevara-Patiño JA; Montgomery SC; Perales MA; Maughan MF; Dempsey J; Donovan GP; Olson WC; Houghton AN; Wolchok JD
Clin Cancer Res; 2005 Nov; 11(22):8114-21. PubMed ID: 16299244
[TBL] [Abstract][Full Text] [Related]
4. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
[TBL] [Abstract][Full Text] [Related]
5. Impact of a Plasmid DNA-Based Alphavirus Vaccine on Immunization Efficiency.
Lundstrom K
Methods Mol Biol; 2021; 2197():33-47. PubMed ID: 32827131
[TBL] [Abstract][Full Text] [Related]
6. Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines.
Diebold SS; Schulz O; Alexopoulou L; Leitner WW; Flavell RA; Reis e Sousa C
Gene Ther; 2009 Mar; 16(3):359-66. PubMed ID: 19052633
[TBL] [Abstract][Full Text] [Related]
7. A novel DNA vaccine based on ubiquitin-proteasome pathway targeting 'self'-antigens expressed in melanoma/melanocyte.
Zhang M; Obata C; Hisaeda H; Ishii K; Murata S; Chiba T; Tanaka K; Li Y; Furue M; Chou B; Imai T; Duan X; Himeno K
Gene Ther; 2005 Jul; 12(13):1049-57. PubMed ID: 15800663
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis.
Yin X; Wang W; Zhu X; Wang Y; Wu S; Wang Z; Wang L; Du Z; Gao J; Yu J
Biochem Biophys Res Commun; 2015 Sep; 465(2):239-44. PubMed ID: 26253468
[TBL] [Abstract][Full Text] [Related]
9. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ
Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.
Leitner WW; Hwang LN; Bergmann-Leitner ES; Finkelstein SE; Frank S; Restifo NP
Vaccine; 2004 Mar; 22(11-12):1537-44. PubMed ID: 15063579
[TBL] [Abstract][Full Text] [Related]
11. Self-replicating alphavirus RNA vaccines.
Ljungberg K; Liljeström P
Expert Rev Vaccines; 2015 Feb; 14(2):177-94. PubMed ID: 25269775
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.
Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Polo JM; Slater LA; Ling M; Wu TC
Hum Gene Ther; 2002 Mar; 13(4):553-68. PubMed ID: 11874633
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Ling M; Slater LA; Roden RB; Wu TC
Hum Gene Ther; 2001 Feb; 12(3):235-52. PubMed ID: 11177561
[TBL] [Abstract][Full Text] [Related]
14. Tumor immunity and autoimmunity induced by immunization with homologous DNA.
Weber LW; Bowne WB; Wolchok JD; Srinivasan R; Qin J; Moroi Y; Clynes R; Song P; Lewis JJ; Houghton AN
J Clin Invest; 1998 Sep; 102(6):1258-64. PubMed ID: 9739060
[TBL] [Abstract][Full Text] [Related]
15. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma.
Steitz J; Brück J; Steinbrink K; Enk A; Knop J; Tüting T
Int J Cancer; 2000 Apr; 86(1):89-94. PubMed ID: 10728600
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
Leitner WW; Ying H; Driver DA; Dubensky TW; Restifo NP
Cancer Res; 2000 Jan; 60(1):51-5. PubMed ID: 10646851
[TBL] [Abstract][Full Text] [Related]
17. Alphavirus-based vaccines.
Lundstrom K
Curr Opin Mol Ther; 2002 Feb; 4(1):28-34. PubMed ID: 11883692
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
19. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
20. Replicase-based DNA vaccines for allergy treatment.
Scheiblhofer S; Weiss R; Gabler M; Leitner WW; Thalhamer J
Methods Mol Med; 2006; 127():221-35. PubMed ID: 16988457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
